Adipotide
$Animal/nonhuman-primate efficacy signal; Phase 1 initiated; No published human obesity-efficacy data; Renal safety concern
Adipotide is not an appetite suppressant, GLP-1, or ordinary “cutting” peptide. It is designed to injure the blood vessels that support white fat. That mechanism is why kidney safety and off-target injury concerns dominate the entry.
It is a targeted pro-apoptotic fat-vasculature compound. The animal data are notable, especially the obese-rhesus-monkey study, but the mechanism is tissue injury rather than reversible hormone signaling. Human development reached a Phase 1 setting in obese metastatic prostate-cancer patients, but no peer-reviewed human obesity-efficacy or routine-safety results were identified.
Consider the renal-toxicity and human-data-gap sections before the weight-loss section. Do not treat community microgram protocols as validated equivalents to primate research dosing.
Classification details
- Adipotide, also called FTPP, prohibitin-TP01, or TP01, is a synthetic chimeric pro-apoptotic peptidomimetic, not an endogenous signaling peptide and not a GLP-1, stimulant, lipolytic, or appetite suppressant.
- The core research identity is a fat-homing CKGGRAKDC motif joined by a GG linker to a pro-apoptotic KLAKLAK repeat payload. The monkey-paper sequence is commonly written CKGGRAKDC-GG-D(KLAKLAK)2.
- The scientific concept is targeted injury to white-adipose-tissue vasculature. This makes it qualitatively different from metabolic peptides that reversibly activate a receptor.
- Human development reached an initiated/dosed Phase 1 oncology/obesity safety study, but no peer-reviewed human obesity-efficacy or routine-safety results were identified. Do not summarize it as having established human fat-loss efficacy.
- Adipotide is a pro-apoptotic peptidomimetic aimed at adipose vasculature, not a metabolic hormone, GLP-1 alternative, or ordinary fat-loss peptide.
- The CKGGRAKDC homing sequence was selected for white-fat vasculature and is associated with prohibitin biology in adipose endothelial tissue.
- After binding/internalization, the KLAKLAK payload is intended to disrupt mitochondrial integrity and induce apoptosis in targeted vascular cells.
- The downstream result in animal models is loss or rarefaction of adipose blood supply, followed by reduction/resorption of the supported white fat depot.
- Prohibitin is a multifunctional protein and the PHB/ANXA2/CD36 system participates in fatty-acid transport. Do not overstate the target as universally fat-exclusive or human-validated for safe selectivity.
- The central idea is targeting prohibitin-associated markers in white-adipose vasculature and delivering a pro-apoptotic KLAKLAK payload after internalization.